
|Videos|September 9, 2021
Should NPDR patients be treated with anti-VEGF agents?
Author(s)OTE Staff Reports
Dr Jennifer Sun explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).
Advertisement
Dr Jennifer Sun, associate professor of Ophthalmology, Harvard Medical School; chief at the Center for Clinical Eye Research and Trials, Joslin Diabetes Center, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
DEX implant shows benefit across RVO subgroups in real-world retrospective study
2
European Dry Eye Society Congress 2026: real-world evidence on Artelac Complete in dry eye disease
3
Lumvoa gains US FDA approval for thyroid eye disease with class-first broad label
4
Study examines accommodation after iris-fixated phakic IOL implantation
5

























